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Background: Genetic variants of the genes encoding Human Immunodeficiency Virus-1 (HIV-1) co-receptors and their
ligands, like CC-Chemokine Receptor 5 delta 32 mutation (CCR5-Delta32), CCR5 promoter A/G (Adenine/Guanine),
CC-Chemokine Receptor 2 mutation 64 isoleucine (CCR2-64I) and the Stromal cell-derived Factor 3’A mutation
(SDF1-3’A), are involved in the susceptibility to HIV-1 infection and progression. The prevalence of these mutations
varies by Region. However, little is known about their distribution in the population of Dschang, located in the West
Region of Cameroon. The prevalence of HIV in the West Region of Cameroon is lower than elsewhere in Cameroon.
The objectives of this study were to determine the distribution of four AIDS Related Gene (ARG) variants in HIV-infected
and non-infected population of Cameroon especially in the West Region and to estimate the contribution of these
variants to the susceptibility or resistance to HIV infection. We also aimed to evaluate the effectiveness of genotyping
using dried blood spot (DBS) samples.
Methods: A total of 179 participants were recruited from two hospitals in Dschang in the West Region of Cameroon.
Their genotypes for CCR5-Delta32, CCR5 promoter 59029A/G, CCR2-64I and SDF1-3’A were analyzed using polymerase
chain reaction (PCR) and restriction fragment length polymorphisms.
Results: A total of 179 participants were enrolled in the study. Among them, 32 (17.9%) were HIV positive and 147
(82.1%) were HIV negative. The allelic frequencies of these genes were: 0%, 49.72%, 17.6% and 100% respectively for
CCR5-Delta32, CCR5 promoter 59029A/G, CCR2-64I and SDF1-3’A. No individual was found to carry the CCR5-Delta 32
mutation. All participants recruited were heterozygous for the SDF1-3’A allele.
Conclusion: Our data suggest that the CCR5-Delta32 cannot account for the protection as it was completely absent in
our population. SDF1-3’A variants, may be in association with other polymorphisms, may account for the overall
protection from HIV-1 infection in participants recruited as everyone carries this allele. The CCR5 promoter 59029 G/G
genotype may be associated with the risk for HIV-1 infection in this population, while the CCR2-64I (A/A genotype) may
account for the protection against HIV infection. The results of genotyping from fresh blood and DBS were comparable.
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Thirty years after the discovery of HIV as the cause of
AIDS there is still no effective vaccine and no cure for
this disease. HIV susceptibility shows a consistent level
of individual heterogeneity, much of which can be con-
ferred by host genetic variation, some to the virus and
some to the immune response. In an effort to discover
host factors required for HIV replication, to identify
crucial pathogenic pathways, and to reveal the full ar-
mament of host defenses, there has been a shift from
candidate-gene studies to unbiased genome-wide gen-
etic and functional studies. However, the number of se-
curely identified host factors involved in HIV disease
remains small, explaining only approximately 15-20%
of the observed heterogeneity [1].
Humans are constantly in contact with infectious patho-
gens. Selective pressure may result in genetic changes
that may be important to escape infections or to better
fight against infection [2].
The unexpected encounter, between HIV and the
chemokine system has dramatically advanced our un-
derstanding of the pathogenesis of AIDS, opening new
perspectives for the development of effective prophy-
lactic and therapeutic measures [3].
A previous survey conducted in 2000 in Cameroon
indicated substantial variation in HIV seroprevalence,
ranging from 0% to 18% among ethnic groups in differ-
ent villages of Cameroon [4]. A recent report from the
national HIV/AIDS committee showed differential HIV
prevalence according to the Region; the West Region
where the Bamileke people live has one of the lowest
rates of HIV prevalence at 2.3% [5]. Whether genetic
variation among ethnic groups can account for or reflect
important portions of the differences in HIV seropreva-
lence among groups in Cameroon is unknown. However,
limited information is available about the distribution
among overall African populations of host genetic
polymorphisms conferring resistance to HIV-1 infec-
tion or slowing HIV disease progression. Identifying
CCR2-64I, CCR5-Δ32, CCR5 promoter 59029 A/G and
SDF1-3′A allelic variants and their distribution may
help understand the burden and course of the disease
which may be important in clinical decision making. In
the present study, we investigated four ARG variants,
in the West Region of Cameroon and analyzed the
association of these host gene polymorphisms with
HIV serostatus.
Notably, polymorphisms of the genes for CCR5, CCR2
and stromal-derived factor 1 (SDF1) have been found
to modulate the susceptibility of individuals to HIV-1
infection and/or the pathogenic progression [6]. How-
ever, the real effect of those gene polymorphisms on
the susceptibility of individuals to HIV-1 infection and
AIDS progression remains controversial.Individuals who are homozygous for the mutations
(CCR5-Δ32/Δ32) show high resistance to HIV-1 infec-
tion in many ethnic populations [7-10]. However, recent
studies found that several individuals with the CCR5-
Δ32/Δ32 genotype were HIV-1 positive [11-13]. Further-
more, the distribution of CCR5-Δ32 frequency varies in
different ethnic populations. While a high frequency of
CCR5-Δ32 appears in Caucasians, a very low frequency
is evident in Asian people, [10,14-17] and in Africa [18].
A previous report showed no CCR5-Δ32 allele in seven
ethnic populations in Cameroon [19].
Several other polymorphisms in the CCR5 gene have
been associated with HIV infection, namely the CCR5-
m303, the CCR5-59653T and the CCR5 promoter 59029
A/G. CCR5 promoter 59029 A/G is an A/G transition
identified at base pair 59029 in the CCR5 promoter.
Both promoter alleles are common (43-68% allelic fre-
quency for 59029-A depending on race) [20]. The CCR5
promoter 59029 A/G distribution and its impact in HIV-
1 infection in Cameroon have not yet been explored.
In HIV-1/AIDS, the mutation of valine (V) to isoleucine
(I) in CCR2 has not been shown to affect susceptibility
to infection, but HIV-infected persons, heterozygous or
homozygous for this mutation appeared to progress to
AIDS or death more slowly [21]. This may not be by its
action directly but, by the linkage to other haplotype
mutations (example CCR5-Δ32, CCR5-59653T). Some
previous studies, however, have not confirmed this ef-
fect on progression to disease [22]. The delay of disease
is achieved through a long asymptomatic phase of the
disease. Studies on infected commercial sex workers in
Nairobi, Kenya, suggested that the presence of the
mutation helped to explain the slow progression in 21%
to 46% of slow progressors [23]. One mutation linked to
the CC-chemokine receptor, CCR2-64I is present mostly
in Africa compared to the rest of world. However, despite
the high prevalence of HIV in Africa, the CCR2-64I
mutation alone is but one possible factor in HIV/AIDS
development. The frequency of this mutation is as follows:
in overall Africa (17.2%), Gambia (4.3%), and Central
Africa (20.2%) [24]. In some Spanish populations the
prevalence is also high (14% - 30%) [25].
SDF1 is the principal ligand of CXCR4. In SDF1-3′A, a
G to A mutation at position 801 relative to the ATG start
codon in the non-coding Region of the SDF-1 gene, has
been shown to inhibit AIDS progression [26,27]. HIV
infected patients homozygous for this mutation exhibited
a significantly delayed progression to AIDS and an even
more significant decrease in mortality [27]. It has been
known that the SDF1-3′A mutation could result in in-
creased SDF1 production, resulting in delayed infection
due to the strong competition with the CXCR-4 chemo-
kine receptor. Other groups, however, did not observe a
similar inhibitory effect, but instead reported that patients
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re-rapid disease progression [28-31]. Importantly, the
frequency of the SDF1-3′A mutation varies in different
ethnic populations [32].
We are reporting in this article the distribution of four
ARG’s in Dschang in the West Region of Cameroon.
Methods
Subjects and sample collection
Participants of both sexes were recruited from patients
consulting at the district hospital and the Saint Vincent de
Paul hospital in Dschang city. Only consenting partici-
pants were enrolled and a questionnaire was administered.
Experimental protocols were approved by the National
ethics committee under the N°269/CNE/SE/2011. Written
informed consent was obtained from each participant. Five
ml of blood were collected in EDTA tubes from each
participant. The plasma was used for the diagnosis of HIV
and the Buffy coat was used as a source of genomic DNA
for genotyping.
HIV testing
The presence of HIV antibodies was detected using Deter-
mine HIV 1/2 test (Alere, 357 Matsuhidai, Matsuda-shi,
Chiba, 270–2214 Japan) and confirmed using the Genie
III HIV-1/HIV-2 test (Biorad 3, Bd Raymond Poincaré,
92430 Marnes La Coquette, France).
Isolation of genomic DNA and genotyping of CCR5-Δ32,
CCR5 promoter 59029 A/G, CCR2-64I and SDF1-3′A
Genomic DNA was extracted from the Buffy coat using
the QiaAmp DNA mini kit (Qiagen S.A 3 Avenue du
Canada, LP 809, 91974 Courtaboeuf Cedex, France),
according to the manufacturer’s instructions.
The CCR5-Δ32, CCR5 promoter 59029 A/G, CCR2-
64I, and SDF1-3′A genetic variants in individual subjects
were characterized by PCR followed by RFLP detection
using the specific primers and restriction endonucleases as
described previously [33,34]. The sequences of primersTable 1 Primers, amplicon size, enzymes, expected fragments










CCR2-64I GGATTGAACAAGGACGCATTTCCCC 380 FokI
TTGCACATTGCATTCCCAAAGACCC
SDF1-3’A CAGTCAACCTGGGCAAAGCC 302 MspI
AGCTTTGGTCCTGAGAGTCCand the restriction enzymes used are presented in Table 1.
All restriction enzymes used in this work were purchased
from New England Biolabs, 240 County Road, Ipswich,
MA, 01938–2723, USA, and used according to their
instructions.
The CCR5-Δ32 gene fragment amplified by the above
mentioned primers will produce two types of fragments
and three types of genotypes depending on the presence
or not of the mutation: a 262 bp fragment if the person
does not have the Δ32 mutation on its two alleles (wild
type), a 230 fragment if the person is homozygous for
the deletion (mutant) and two fragments 262 and 230 if
the person is heterozygous.
The CCR5-promoter 59029 A/G fragment amplified by
the above mentioned primers is 498 bp. The A to G
mutation introduces a recognition site for the Bsp1286I
restriction enzyme. If there is mutation, then Bsp1286I
will cleave and produce two fragments of 453 and 45 bp
respectively if the person is homozygous for the mutation.
If the person is heterozygous there will be three fragments
on the gel of 498 bp, 453 bp and 45 bp respectively. If a
person has the wild type allele, then only one fragment
of 498 bp will be seen on the gel.
The CCR2 gene fragment amplified by the primers in
Table 1 is 380 bp. The 64I mutation introduces a recog-
nition site for FokI. In this case, FokI will cleave at its
recognition site and produce two fragments of 215 and
165 bp respectively if the person is homozygous for the
mutation. If a person is heterozygous there will be three
fragments on the gel at 380 bp, 215 bp and 165 bp re-
spectively. There will be just one fragment at 380 bp if
the CCR2 gene fragment does not have the mutation.
The SDF1-3′A gene fragment amplified by the designed
primers (in Table 1) is 302 bp. The A to G mutation re-
moves the recognition sequence specific for MspI. If there
is a mutation, then the enzyme MspI will not cleave and
only the 302 bp fragment will be present. If the person
does not carry the mutation (homozygous wild type); the
MspI digestion will produce two fragments of 202 and 100size after digestion and references used for genotyping
me used
he RFLP
Expected fragments size (bp) Reference
262 or 230 [33]Kristiansen et al., 2001
286I 453 + 45 [33]Kristiansen et al., 2001
215 +165 [34]Magierowska et al., 1999
202+ 100 [33]Kristiansen et al., 2001
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three fragments on the gel at 302 bp, 202 bp and 100 bp
respectively.Genotyping using DBS samples
To evaluate the performance of genotyping using DBS
samples, 50 random blood samples were spotted on
Whatman paper and allowed to dry at room temperature
in the dark [35]. DNA extraction was done on these
DBS using a QiaAmp DNA minikit according to the
manufacturer’s instruction. Eluted DNA was amplified
and digested as described above. This evaluation was
done on the CCR2-64I gene. Results obtained were com-
pared to those obtained from fresh Buffy coat.Statistical analysis
The allelic frequencies were calculated as (h + 2H)/2N,
where H is the number of samples with a homozygous
mutation genotype, h is the number with a heterozygous
mutation genotype and N the total number of samples.
The frequency was further analyzed by Hardy–Weinberg
equilibrium (HWE) analysis. The HWE was performed
in the population using PopGen software. The differ-
ences in the frequency of each genetic variant between
HIV-1 seronegative and HIV-1 seropositive groups were
determined by a Chi-square test. A value of P < 0.05 was
considered statistically significant.Table 3 Distribution of CCR5-Δ32, CCR5 promoter 59029
A/G, CCR2-64I and SDF1-3′A in HIV seropositive
and seronegative groups




CCR5-Δ32 Wt/wta 32 (100) 147 (100)
Wt/Δ32b 0 (0.0) 0 (0.0)
Δ32/Δ32c 0 (0.0) 0 (0.0)Results
Study population
To determine the distribution of CCR5-Δ32, CCR5 pro-
moter 59029 A/G, CCR2-64I and SDF1-3′A genetic vari-
ants, we recruited 179 subjects living in Dschang in the
West Region of Cameroon, who were either HIV-1 sero-
positive or seronegative. They were all aged between 16
and 81 years old, with the median age of 27. There were
123 (68.7%) female and 56 (31.3%) male. The epidemio-
logical characteristics of the subjects are presented in
Table 2.Table 2 Demographic characteristics of study participants
according to the HIV-1 sero status, age and sex
Female Male Total Overall
Age groupa HIV+ HIV- HIV+ HIV- Female Male
16-24 6 43 3 21 49 24 73
25-34 10 36 0 17 46 17 62
35-44 8 13 4 2 21 6 27
45-54 1 2 0 9 3 9 12
55-81 0 4 0 0 4 0 5
Total 25 98 7 44 123 56 179
a.years.HIV serology
From the 179 participants, 147 (82.1%) were HIV nega-
tive. Thirty two were confirmed to be HIV positive
(17.9%) of which 25 were female and 7 were male. 41%
of the HIV positive participants were already on ARV
treatment.Evaluation of the genotyping using DBS
DNA extraction was done successfully from dried blood
spots. The amplification of the 380 bp of the CCR2 gene
fragment was done according to the method developed
by Magierowska [34]. The results obtained were 100%
concordant with those obtained from fresh blood. So
DBS samples can be confidently used for genotyping.Genotyping
The allelic frequencies of CCR5-Δ32 (0%), CCR5 pro-
moter 56029 A/G (49.72%), CCR2-64I (17.60%) and
SDF1-3′A (100%) in the population were reported.
These results are presented in Table 3 for the whole
population and Table 4 according to the HIV serostatus.
No CCR5-Δ32 mutation was identified in our study
group either as homozygous or heterozygous. For the
CCR5 promoter 59029 A/G, prevalence of 62.6% of het-
erozygous, 17% of wild type and 18.4% double mutant
were identified in our study group. This is the first
description of the prevalence of this ARG variant in
Cameroon. The prevalence of 2.7%, 29.6% and 67.6%
was found respectively for the CCR2-64I homozygous
mutant, heterozygous and homozygous wild type. For
the SDF1-3′A gene neither wild type nor homozygousCCR5 promoter 59029 A/G A/Aa 5 (15.62) 29 (19.72)
A/Gb 17 (53.12) 95 (64.62)
G/Gc 10 (31.25) 23 (15.64)
CCR2-64I G/Ga 24 (75) 97 (66.1)
G/Ab 8 (25) 45 (30.6)
A/Ac 0 (0.0) 5 (3.4)
SDF1-3’A G/Ga 0 (0.0) 0 (0.0)
G/Ab 32 (100) 147 (100)
A/Ac 0 (0.0) 0 (0.0)
a. Wild type homozygotes.
b Heterozygotes.
c Mutant type homozygotes.















CCR2 wta 295 174 0,824
CCR2 mtb 63 58 0,176
SDF1-3’A 179 179 1
* AIDS related gene. a. Wild type. b Mutant.
Table 6 Allelic frequencies of CCR5 promoter A/G and
CCR2 64I and HIV serostatus in a population of
west Cameroon
Allelic genotypes HIV Seropositive HIV Seronegative Total
Freqa% x2 P Freq% x2 P Freqa%
CCR5 P*
A/G
CCR5 wt 42,19 0,747 0,387 52,04 0,044 0,832 50,27
CCR5 mt 57,81 0,794 0,372 47,96 0,034 0,853 49,72
CCR2 64I CCR2 wt 87,5 0,834 0,36 81,3 0,979 0,322 82,38
CCR2 mt 12,5 0,476 0,49 18,7 0,662 0,415 17,62
*. Promoter.
a. Frequency.
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a heterozygous genotype.
The HWE analysis revealed that all genetic variants for
CCR5 promoter 59029 A/G and CCR2-64I in the studied
population were in equilibrium (P > 0.05) (Table 5).Allelic frequencies and HIV serostatus
Allelic frequencies in relation to the HIV serostatus are
presented in Table 6. The allele frequency of the CCR5
promoter 59029 A/G in HIV-1 seropositive group (57.8%)
was not significantly different from that (48.6%) in the
seronegative group (P = 0.19). Importantly, there was a
significant difference in G/G genotype between HIV-
seropositive and HIV seronegative (34.3% and 15.6%
respectively, P= 0.049), suggesting that the CCR5 pro-
moter 59029 G/G allele may be associated with the risk
of HIV-1 infection in our population. This is contra-
dictory to a previous study where the CCR5 promoter
59029-G/G appears to be protective relative to CCR5
59029-A/A [20].Table 5 Allele frequency and HWEa analysis of four ARGb















CCR5-Δ32 Wt 100 100 100




A 42.2 0.54 0.675 51.4 12.6 0.001 46.8
G 57.8 48.6 53.2
CCR2- 64I G 87.5 0.74 0.207 81.3 0.16 0.75 84.4
A 12.5 18.7 15.6
SDF1-3’A G 50 300.25 50 300.25 50
A 50 50 50
a. Hardy-Weinberg equilibrium. b AIDS related gene.The allele frequency of CCR2-64I in the HIV-1 sero-
negative group (18.7%) was not significantly higher than
that (12.5%) in seropositive group (P = 0.22). This suggests
that the CCR2-64I allele is unlikely to be associated with
the low prevalence of HIV-1 infection in our population.
Discussion
In our study we have recruited a total of 179 participants,
on which the HIV serology test has been performed. We
obtained 32 HIV positive patients and 147 HIV negative
ones. This gave a seroprevalence of 17.9% higher than the
general prevalence of the west Region that is at 2.3% [5].
This is explained by the fact that our participants were en-
rolled among patients consulting at hospitals.
The evaluation of the methodology using DBS in com-
parison to fresh blood sample was done using the test of
Kappa concordance. The kappa of concordance was 0.95
(p = 0.00), which means that there was a high concord-
ance between the two methods. So DBS can be used for
ARG genotyping.
Studies have revealed a differential distribution of ARG
variants according to ethnicity [32]. In particular, it was
reported that the frequency of the CCR5-Δ32 was high in
Caucasians, but low or even absent in Asians and Africans
[18]. The distribution of the CCR2-64I allele in South
Africans was 13%, and in African populations of Kenya
it ranged from 21% to 23%, [23,36] and in 7 ethnicities
of Cameroon from 0 to 7.1% [19]. The frequency of
SDF1-3′A ranged widely across ethnic groups, from 3%
to 71% worldwide and from 3% to 9% in Africans [32].
Data on the different genetic frequencies of CCR5-Δ32,
CCR5 promoter 59029 A/G, CCR2-64I and SDF1-3′A
alleles reported in African populations living in different
African countries are however sparse. The present study is
the second to describe the distribution of CCR5-Δ32,
CCR2-64I and SDF1-3′A in Cameroon. It is the first to
describe these distributions in the West Region and that
of the CCR5 promoter 59029 A/G in Cameroon.
Since no CCR5-Δ32 allele was found in our population
it could not account for the low HIV prevalence in the
West Region of Cameroon. As shown by the study of
Table 7 Combination of the gene variants of CCR5
promoter A/G and CCR2 64I and HIV serostatus in a
population of west Cameroon






Wt (A/A) Wt (G/G) 4 16 0.760
Mt (G/G) Wt (G/G) 9 24 0.134
Wt (A/A) Mt (A/A)
Hetero
(A/G)





Wt (G/G) 12 70 0.305
Wt (A/A) Hetero
(G/A)







Wt: wild type, Mt: mutant, Hetero: heterozygote.
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as in our study population).
About 50% (49.72%) of our population carry the CCR5
promoter 59029 A/G mutation. Looking at the distribu-
tion of CCR5 promoter 59029 A/G between the HIV
positive and HIV negative, the allelic frequency was the
same for the HIV positive and the HIV negative group.
But the homozygote G/G seems to be higher in HIV
positive group, contradicting previous findings [20].
The distribution of the CCR2-64I in our study popula-
tion was 17.6%, compared to 31.3% obtained by Ma [19],
from 7 ethnic populations in the South and Central Re-
gions of Cameroon. This mutation is thus high in the
Central and South Regions of Cameroon compared to
the West Region.
Because in HIV positive and HIV negative individuals
the distribution of this allele was the same, this mutation
confers no resistance to HIV infection but may be
involved in the progression of HIV infection to AIDS.
Ma [19] et al. in 2005 found that CCR2-64I delays pro-
gression of HIV disease to AIDS and death in men and
not in women, by conditional logistic regression analysis
with matching on ethnicity and adjustment for differences
in age. But a meta-analysis, based on all the published
works on CCR2-64I in relation to susceptibility to HIV
infection, has concluded that this allele has no effect on
reducing the risk of HIV-1 infection [37]. Instead, it
may act with CCR5-Δ32 as haplotypes in delaying HIV
infection progression to AIDS [34,38].
We have obtained 100% frequency of SDF1-3′A in our
study population compared to 0–7.1% obtained by Ma
et al., 2005. Could this high prevalence contribute either
alone or linked to another gene as a haplotype to the low
prevalence of HIV in this group? This result may be spe-
cific to the population studied and also to the small size of
the population that may be not representative. We intend
to extensively investigate the occurrence of this gene in all
10 Regions of Cameroon and on a larger population. Such
a larger study may lead to an explanation for our current
results. If the exclusive presence of this one allele is con-
firmed, this may have been selected in an early population
that was exposed to HIV or some related disease and the
beneficial mutation transmitted from generation to gener-
ation. A high frequency of SDF1-3′A (71%) was also ob-
served in the Oceanian population in New Guinea, [32]
where the human presence dates back at least 40,000 years
to the oldest human migrations out of Africa. The preva-
lence of HIV in Papua New Guinea was 1.5% in 2007 and
it decreased to 0.9% in 2009.
The CCR5-Δ32 and CCR2-64I alleles have been shown
to have a strong protective effect on progression of HIV-
1 infection, but SDF1-3′A homozygosity carried no such
protection [31]. This mutation is associated with the on-
set of AIDS progression. The protective effect of CCR2-64I is dominant, whereas that of SDF1-3'A is recessive.
Surprisingly, the SDF1-3'A homozygote has also shown
a possible protection against HIV-1 infection [26,27].
Based on the small size population studied, SDF1-3′A
heterozygosity may contribute to low HIV/AIDS infec-
tion in the West Region of Cameroon.
The combinations of the genotype at loci CCR5 pro-
moter and CCR2 in HIV positive individuals and HIV
negative individuals were analyzed. As shown in theTable 7,
P values of 0.760, 0.134, 1, 0.305 and 0.814 were obtained
for the five combinations. These results demonstrate that
none of the combinations can account for the low preva-
lence of HIV in the West Region of Cameroon.
The χ2 tests show that the CCR5 promoter 59029 A/G
and CCR2-64I polymorphism were in equilibrium from
generation to generation (the X2 value > 3.84). The ob-
served genotype frequencies had no significant differ-
ence from the frequencies expected in each group of
polymorphisms. In light of the prevalence of these muta-
tions we can say that these mutations were present in
our population since early times. The presence of these
mutations worldwide would imply that these mutations
arose prior to the dispersal of modern Homo sapiens
from an African ancestral population more than 100 000
years ago [32].
It is known that following infection with HIV-1, the
rate of clinical disease progression varies between indi-
viduals. Factors such as host susceptibility, genetics and
immune function [39], health care and co-infections
[40], as well as viral genetic variability [41], may affect
the rate of progression to AIDS. Many studies have
looked at the genetic viral distinctions that might explain
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gating the viral genotype has focused on deletions in the
nef gene of HIV seen in some nonprogressors. While many
researchers have observed defective nef gene alleles in long
term nonprogressors (LTNP), others have not [42-45].
Other researchers have focused on human leukocyte anti-
gen (HLAmolecules [34,46,47]. All these factors inter-
play to affect the acquisition the resistance or the
progression into HIV/AIDS.
Conclusion
In summary, we investigated the distribution of four ARG
variants in HIV seropositive and seronegative population.
Not surprisingly, we found no CCR5Δ32 allele. Surpris-
ingly, all the subjects exhibited the SDF1-3′A mutation as
heterozygous. The frequency of CCR5 promoter G/G in
HIV seropositive was significantly higher than that in HIV
seronegative. Therefore, these data suggest that the CCR5
promoter G/G variant together with other factors may be
associated with a risk for HIV infection. The distribution
of CCR2-64I was similar in HIV positive and HIV-
negative group, and could not be attributed any impact on
HIV in our population.
From the study done on the four ARG variants and in
light of the limited size of the population, further studies
are needed on a larger population to provide more con-
clusive results and to define the role if any of SDF1-3′A
in HIV prevalence in our population. Other ARG should
also be studied including HLA gene families, as the ef-
fects of the gene variants are likely to be associative.
In light of the disparities in the distribution of ARG by
ethnicity, and the contradictory effect of these ARG’s on
HIV susceptibility or progression, we suggest that studies
be done on more population groups and that ethnicity
must be taken into account. A more extensive meta-
analysis on larger data sets may lead to conclusive results.
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